Data management in drug development means capturing, curating and connecting omics, clinical and real-world data generated at every stage of the pipeline, from target identification through post-market surveillance, so that results stay accurate, reproducible and audit-ready.

Multi-omics can reveal complementary layers of disease biology and drug response. Still, it also creates a practical challenge: each assay produces data with its own scale, structure, metadata and quality constraints.¹

Digital health technologies add another stream of information, including remotely captured measures and patient-reported data. Used well, these sources can broaden the view beyond scheduled site visits; used poorly, they introduce noise, missingness and uncertain context.²

The goal is not simply to collect more data. It is to preserve enough context, quality and lineage for teams to compare results, challenge assumptions and decide which evidence is ready to move forward.

Bringing a new drug from discovery to market typically takes a decade or more. At the same time, cost estimates vary widely, from under $1 billion to several billion dollars per approved product, depending on the methodology, therapeutic area and whether failed programs and the cost of capital are included. Because only a minority of candidates entering clinical development ultimately gain approval, reliable, decision-ready data can help teams reduce avoidable delays and make better-informed development decisions.

Integration of Complex Data in the Drug Discovery and Development Pipeline

No single dataset covers the entire program from target selection to post-market monitoring. Discovery teams may begin with molecular profiles and screening results; clinical teams add safety, efficacy and operational data; later analyses may incorporate information collected in routine care. The value comes from connecting the right evidence at the right decision point without losing its provenance.

• Target identification, hit discovery and lead optimization: Multi-omics and screening data can reveal target–pathway relationships, support candidate prioritization and expose liabilities that warrant follow-up testing.¹
• Preclinical development, clinical trials and regulatory submission: Nonclinical and clinical evidence inform assessments of safety, activity and benefit–risk. Submission preparation then requires traceable transformations, controlled terminology and datasets structured to applicable standards, not simply a final formatting step.³
• Post-market surveillance: Data from routine care, registries, claims and digital health technologies can help characterize safety and effectiveness after approval. Whether those data can support a regulatory conclusion depends on their relevance, reliability and the design of the analysis.⁴

This is less a shift to a fully “data-driven” model than a change in how evidence is assembled. Computational methods, shared platforms and remote data capture can make the pipeline more connected, but only when teams agree on standards, ownership and acceptable uses of the data.

Data Curation, Integration and Sharing

Strategies and Importance

Curation is where raw output becomes usable evidence. Teams resolve identifiers, document transformations, retain provenance and decide which records are suitable for a particular analysis. The recurring obstacles are familiar different formats, uneven metadata, duplicate records and inconsistent quality checks, but the remedy is not a single platform. It is a governed process that makes assumptions and changes visible.

Tools

Different tools address different parts of that process:

• Electronic Lab Notebook (ELN) systems for structured, digital documentation of experiments, improving traceability and reproducibility
• Centralized data management platforms for unified access to diverse datasets across departments
• Data management software for handling complex datasets, supporting compliance and making datasets compatible with computational tools and analytics platforms

Understanding Diverse Data Types in Drug Discovery

Drug discovery data differ not only in subject matter but also in structure, resolution and intended use. Common sources include:⁸

• Omics data genomics, proteomics, metabolomics and transcriptomics for studying disease biology, evaluating targets, discovering biomarkers and investigating mechanisms of action. Chemical screening for compound evaluation and lead optimization
• Patient-derived samples and clinical observations for characterizing response, resistance and disease heterogeneity. Electronic health records, mobile health and digital platforms to monitor patients outside controlled experimental settings

Data Complexity and Challenges

The hardest integration problems rarely come from volume alone. A single study may combine instrument files, tabular assay results, images, clinical notes and derived analysis outputs, each with different identifiers, metadata and quality rules.⁸

Three practical questions help frame the response:

• Can the infrastructure store, transfer and process the expected data volume without creating bottlenecks?
• Are identifiers, formats and metadata consistent enough to compare records across sources?
• Which steps should be automated and where is expert review still needed to interpret exceptions or uncertain results?

Data Management and Quality across the Discovery Pipeline

Foundations of Effective Data Management

Good data management begins before an experiment runs. Teams need to know which source files and metadata to retain, how derived results will be traced back to them and what quality checks are appropriate for the decision at hand. Those controls support reproducibility and regulatory readiness, but they must be matched to the study, system and intended use. ³

Effective data management in drug development, from preserving raw instrument output through analysis and preparation of submission-ready datasets, depends on consistent data-integrity principles and fit-for-purpose validation, standardization and governance across the data lifecycle.

Infrastructure and Systems

Research infrastructure has to accommodate both large files and frequent handoffs among instruments, analysis environments and teams. Cloud-based platforms can add scalable storage and controlled remote access, but centralization does not automatically produce consistency or security. Integration design, identity management, encryption, backup, monitoring and validation still determine how safely and reliably the environment operates.^9,10

Workflow and Automation

Automation earns its value on repeatable steps: capturing instrument output, applying routine quality checks, annotating records and moving approved data between systems. It can reduce manual transcription and shorten handoffs. Exceptions, changes to source formats and regulated decisions still require monitoring, documented controls and human review.¹¹

Best Practices and Compliance

Tools can enforce a rule, but they cannot decide which rule is scientifically appropriate. That responsibility remains distributed across the people who generate, steward, analyze, quality-check and submit the data.

Responsibility for these practices is typically shared across data managers, data stewards, scientists, quality, information technology and regulatory functions, with ownership varying by development stage and data domain. Clinical data managers generally oversee clinical-trial data collection, cleaning and database readiness, while data stewards help define and maintain data standards, quality rules, metadata and access controls across systems.

FAIR principles offer a useful design lens for making preclinical data findable, accessible under appropriate conditions, interoperable and reusable. They are not, however, a regulatory compliance framework or a substitute for study-specific quality controls.¹²

In regulated environments, teams apply ALCOA+ data-integrity attributes Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring and Available to applicable records throughout the data lifecycle. FAIR principles can complement these controls by improving data findability, accessibility, interoperability and reuse, but neither framework alone makes records audit-ready; documented procedures, validated systems, access controls, audit trails and ongoing oversight are also required.

Clinical data management adds participant protection, protocol compliance and submission requirements to the same underlying need for reliable, traceable records. The applicable controls depend on the study design, data source and regulatory use. ³

Data Analysis and Computational Methods for Insight Generation

Core Analytical Methods

Data analytics is fundamental to drug discovery and development, helping researchers derive decision-relevant evidence from complex datasets. Applications include:

• Identifying associations between molecular targets, pathways and phenotypes
• Prioritizing compounds using experimental evidence and validated computational models
• Estimating potential clinical outcomes and sources of uncertainty to inform study design and development decisions

Together, these approaches support hypothesis generation, testing and evidence-based prioritization; experimental or clinical studies are still needed to validate key findings. Data visualization complements the analyses by presenting complex omics, preclinical and clinical data in interpretable formats that can support communication and decision-making across the drug development lifecycle.

Advanced Computational Tools

Computational methods are most useful when they narrow the next experimental question rather than replace it.

• Cheminformatics and computer-aided drug design (CADD) can help prioritize compounds, explore structure–activity relationships and propose modifications for experimental testing¹³
• High-throughput screening couples automated experimentation with data processing to test large compound libraries and identify hits for confirmation¹⁴
• Knowledge graphs and network-analysis tools can connect entities such as genes, proteins, pathways, compounds and phenotypes, making relationships easier to query and investigate¹³

Their outputs are starting points for investigation. Promising associations still need biological interpretation and experimental confirmation.

AI-Driven Insight Generation

AI is already being applied across nonclinical, clinical, manufacturing and post-market work. In discovery, models may estimate ADME properties, surface potential drug–protein relationships or help segment patients using molecular and clinical features. Performance is not uniformly better than conventional approaches; it depends on the task, comparator, training data and context of use. ^15-17

Embedding a model in a workflow can make predictions available at the point of decision. Still, it also creates ongoing responsibilities: versioning the model, monitoring drift, documenting inputs and keeping people accountable for the final interpretation. Scale without those controls can spread error as efficiently as insight.

For a closer look at how these algorithms are applied stage by stage, see AI in Drug Discovery and Development.

Featured Product

Translational Research, Biomarker Discovery and Multi-Omics Integration

Bridging Research to Clinical Outcomes

Translational research asks whether a finding observed in a model system is relevant to human disease and measurable in a clinical setting. Omics profiles, digital measures and clinical observations can help define endpoints or biomarkers, but the path is rarely linear. Candidate biomarkers must be analytically validated and then shown to be clinically meaningful for their intended use. ¹⁸

Combining molecular, clinical and real-world datasets can support diagnostic or prognostic model development in areas such as oncology, infectious disease and metabolic disorders. Generalizability still has to be tested across sites, platforms and patient populations.^19-21

Shared cloud environments can make collaboration easier by providing research groups with controlled access to shared data and analysis resources. Standardization, however, comes from agreed models, metadata and governance, not from the hosting environment itself.²²

Ensuring regulatory compliance and reproducibility

Standards and Submission-Readiness

Regulators need to understand what was measured, how the data changed during processing and whether the evidence supports the sponsor’s conclusion. Standardized datasets and controlled terminology can make that review more efficient, but submission readiness also depends on complete documentation, traceable derivations and a clear explanation of methods and limitations.³

Systems that create, modify, maintain or transmit regulated records should be assessed and controlled for their intended use. GCP, GLP and 21 CFR Part 11 apply in different circumstances; they are not a single universal checklist for every research system. Documentation, version control, role-based access, audit trails and appropriate security controls help maintain trustworthy records.²³

Real-World Data, Digital Health and Post-Market Surveillance

Applications in Pharmacovigilance

Approval does not end the evidence lifecycle. Data management continues through safety surveillance, required post-market studies and evaluations of how a medicine performs in routine care.

Electronic health records, claims, registries and digital health technologies are sources of real-world data. Real-world evidence is produced only after those data are analyzed to answer a defined question about a product’s use, benefits or risks. Because routine-care data were not necessarily collected for that question, relevance, reliability and potential bias must be assessed before concluding.⁴

Digital health technologies can contribute to measures of treatment use, symptoms or physiologic status between clinic visits. They may strengthen safety monitoring, but they do not replace established adverse-event reporting, clinical assessment or signal evaluation. Missing data, device performance and patient adherence all affect interpretation.²

Useful post-market evidence often crosses organizational boundaries. Sponsors, healthcare providers, data partners and regulators need clear agreements on permissible use, common definitions, privacy protections and responsibility for follow-up. Without that groundwork, combining more sources can create a larger dataset without producing a clearer safety signal.²

Emerging Trends

Innovation in Data Infrastructure

The next phase of data infrastructure is being shaped by a practical constraint: research groups need to scale without losing control of provenance, access or reproducibility.

Cloud platforms are one response. They can reduce dependence on local hardware and give distributed teams access to shared storage and computing resources. Their real advantage emerges when data lineage, permissions and interfaces are designed coherently across the environment. ²⁴

AI-assisted bioinformatics and cheminformatics are also moving closer to routine workflows. Models can help triage compounds or highlight patterns in large biological datasets, while automation can execute standardized calculations at scale. Neither eliminates the need to examine assay quality, domain applicability and unexpected results.¹³

For teams, the useful question is not whether a platform is “intelligent” or “real-time.” It is whether the system delivers trustworthy evidence soon enough to change the next decision and makes it possible to reconstruct how that evidence was produced.

References

1. Mukherjee A, Abraham S, Singh A, Balaji S, Mukunthan K. From data to cure: A comprehensive exploration of multi-omics data analysis for targeted therapies. Mol Biotechnol 2025;67(4):1269-1289.
2. Zarour M, Alenezi M, Ansari MTJ, Pandey AK, Ahmad M, Agrawal A, et al. Ensuring data integrity of healthcare information in the era of digital health. Healthc Technol Lett 2021;8(3):66-77.
3. Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H. Role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making. Pharm Res 2022;39(8):1669.
4. Lavertu A, Vora B, Giacomini KM, Altman R, Rensi S. A new era in pharmacovigilance: toward real‐world data and digital monitoring. Clin Pharmacol Ther 2021;109(5):1197-1202.
5. Famili P, Cleary S. Laboratory Information Management System (LIMS) and Electronic Data. Analytical Testing for the Pharmaceutical GMP Laboratory 2022:345-373.
6. Liu W, Li Y, Li X, Wang F, Qi R, Zhu T, et al. Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials. Vaccines 2025;13(3):333.
7. Fu J, Zhang Y, Wang Y, Zhang H, Liu J, Tang J, et al. Optimization of metabolomic data processing using NOREVA. Nat Protoc 2022;17(1):129-151.
8. Coltman NJ, Roberts RA, Sidaway JE. Data science in drug discovery safety: Challenges and opportunities. Exp Biol Med 2023;248(21):1993-2000.
9. Gomase VS, Ghatule AP, Sharma R, Sardana S, Dhamane SP. Cloud Computing Facilitating Data Storage, Collaboration, and Analysis in Global Healthcare Clinical Trials. Rev Recent Clin Trials 2025.
10. Ramapraba PS, Babu BR, Paul NRR, Sharmila V, Babu VR, Ramya R, et al. Implementing cloud computing in drug discovery and telemedicine for quantitative structure-activity relationship analysis. IJECE 2025;15(1):1132-1141.
11. Singh S. Automation of Drug Design and Development. Generative Artificial Intelligence for Biomedical and Smart Health Informatics 2025:73-87.
12. Gadiya Y, Ioannidis V, Henderson D, Gribbon P, Rocca-Serra P, Satagopam V, et al. FAIR data management: what does it mean for drug discovery? Front Drug Discov (Lausanne) 2023;3:1226727.
13. Parikh PK, Savjani JK, Gajjar AK, Chhabria MT. Bioinformatics and cheminformatics tools in early drug discovery. Bioinformatics tools for pharmaceutical drug product development 2023:147-181.
14. Liu C, Zhang H. Data processing for high-throughput mass spectrometry in drug discovery. Expert Opin Drug Discov 2024;19(7):815-825.
15. Rehman AU, Li M, Wu B, Ali Y, Rasheed S, Shaheen S, et al. Role of artificial intelligence in revolutionizing drug discovery. Fundam Res 2025;5(3):1273-1287.
16. Yin J, Qi Y, Zhu F, Zeng S. The Application of Artificial Intelligence in Drug ADME Research. BSP; 2025.
17. Glaab E, Rauschenberger A, Banzi R, Gerardi C, Garcia P, Demotes J. Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review. BMJ open 2021;11(12):e053674.
18. Wichman C, Smith LM, Yu F. A framework for clinical and translational research in the era of rigor and reproducibility. J Clin Transl Sci 2021;5(1):e31.
19. Xu R, Wang J, Zhu Q, Zou C, Wei Z, Wang H, et al. Integrated models of blood protein and metabolite enhance the diagnostic accuracy for Non-Small Cell Lung Cancer. Biomark Res 2023;11(1):71.
20. Bourgonje AR, van Goor H, Faber KN, Dijkstra G. Clinical value of multiomics-based biomarker signatures in inflammatory bowel diseases: Challenges and opportunities. Clin Transl Gastroenterol 2023;14(7):e00579.
21. Veyel D, Wenger K, Broermann A, Bretschneider T, Luippold AH, Krawczyk B, et al. Biomarker discovery for chronic liver diseases by multi-omics–a preclinical case study. Sci Rep 2020;10(1):1314.
22. Hemme CL, Beaudry L, Yosufzai Z, Kim A, Pan D, Campbell R, et al. A cloud-based learning module for biomarker discovery. Brief Bioinform 2024;25(Supplement_1):bbae126.
23. Ladner T, Weh C, Dhillon A, Giffard M, Iacovelli D. Data computation platform (DCP): empowering pharma 4.0 innovation through GxP-compliant and scalable software platform enabling advanced data analytics and real-time process monitoring in regulated environments. J Intell Manuf 2025:1-19.
24. Rehan H. Advancing cancer treatment with ai-driven personalized medicine and cloud-based data integration. J Mach Learn Res 2024;4(2):1-40.